China’s BVCF targets super bacteria
“Large pharmaceutical firms aren’t putting a lot of resources into developing antibiotics nowadays because they can make more money producing drugs for chronic-related diseases, or cancer treatments,” observes Zhi Yang, founder and managing partner of China life sciences-focused GP BVCF. “However, bacteria have grown resistant to most antibiotics.”
Opportunities presented by the need for next-generation antibiotics that combat infections created by "super bacteria" that have developed a resistance to mainstream drugs prompted BVCF to lead a $25 million...
More on Greater China
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.